Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: An editorial

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 7715-7718

  Butera, John A ^a  

^a Hager Biosciences LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; ANTIMYCOBACTERIAL AGENT; ANTIPARASITIC AGENT; BENZAMIDE DERIVATIVE; IMIDAZOLOPIPERAZINE DERIVATIVE; IMIDAZOLOPYRIMIDINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN N MYRISTOYLTRANSFERASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMBINATORIAL CHEMISTRY; DRUG DESIGN; DRUG INDUSTRY; DRUG SCREENING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL SOCIETY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; PROTEOMICS; STRUCTURE ACTIVITY RELATION; TROPICAL DISEASE; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

ANTI-BACTERIAL AGENTS; ANTIPARASITIC AGENTS; CHAGAS DISEASE; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; HUMANS; MALARIA, FALCIPARUM; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PLASMODIUM FALCIPARUM; TROPICAL MEDICINE; TRYPANOSOMA CRUZI; TUBERCULOSIS;

EID: 84886571969     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400443k     Document Type: Article

References (26)

1. Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discovery 2010, 9, 203-214
2. Williams, M. Productivity shortfalls in drug discovery: Contributions from the preclinical sciences? J. Pharmacol. Exp. Ther. 2011, 336, 3-8
3. Khanna, I. Drug discovery in pharmaceutical industry: productivity challenges and trends Drug Discovery Today 2012, 17 (19/20) 1088-1102
4. Collins, F. S. Reengineering translational science; the time is right Sci. Trans. Med. 2011, 3, 90cm17
5. Lee, J. A.; Uhlik, M. T.; Moxham, C. M.; Tomandl, D.; Sall, D. J. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy J. Med. Chem. 2012, 55 (10) 4527-4538
6. Hellerstein, M. K. Exploiting complexity and the robustness of network architecture for drug discovery J. Pharmacol. Exp. Ther. 2008, 325, 1-9
7. Swinney, D. C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discovery 2011, 10, 507-519
8. Reaume, A. G. Drug repurposing through non-hypothesis driven phenotypic screening Drug Discovery Today: Ther. Strategies 2011, 8 (3-4) 85-88
9. Chatterjee, A. K.; Yeung, B. K. S. Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials Curr. Top. Med. Chem. 2012, 12, 473-483
10. Trouiller, P.; Torreele, E.; Olliaro, P.; White, N.; Foster, S.; Wirth, D.; Pécoul, B. Drugs for neglected diseases: a failure of the market and a public health failure? Trop. Med. Int. Health 2001, 6 (11) 945-951
11. Trouiller, P.; Olliaro, P.; Torreele, E.; Orbinski, J.; Laing, R.; Ford, N. Drug development for neglected diseases: a deficient market and a public-health policy failure Lancet 2002, 359, 2188-2194
12. Utzingera, J.; Beckera, S. L.; Knoppa, S.; Blumb, J.; Neumayrb, A. L.; Keiserb, J.; Hatzb, C. F. Neglected tropical diseases: diagnosis, clinical management, treatment and control Swiss Med. Wkly. 2012, 142, w13727 (PDF of the online version, www.smw.ch)
13. Molyneux, D. H. The "neglected tropical diseases": now a brand identity; responsibilities, context and promise Parasites Vectors 2012, 5, 23
14. Hotez, P. J. ASTMH Presidential Address. The four horsemen of the apocalypse: tropical medicine in the fight against plague, death, famine, and war Am. J. Trop. Med. Hyg. 2012, 87 (1) 3-10
15. Guiguemde, W. A.; Shelat, A. A.; Garcia-Bustos, J. F.; Diagana, T. T.; Gamo, F.-J.; Guy, R. K. Global phenotypic screening for antimalarials Chem. Biol. 2012, 19, 116-129
16. Gilbert, I. H. Drug discovery for neglected diseases: molecular target-based and phenotypic approaches. J. Med. Chem. 2013, DOI: 10.1021/jm400362b.
17. Sykes, M. L.; Avery, V. M. Approaches to protozoan drug discovery: phenotypic screening. J. Med. Chem. 2013, DOI: 10.1021/jm4004279.
18. Niepel, M.; Spencer, S. L.; Sorger, P. K. Non-genetic cell-to-cell variability and the consequences for pharmacology Curr. Opin. Chem. Biol. 2009, 13 (5-6) 556-561
19. Cameron, J.; O'Toole, R.; Miller, C. H.; Nisa, S.; Dempsey, S. Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria Antimicrob. Agents Chemother. 2009, 5279-5283
20. Bickle, M. The beautiful cell: high-content screening in drug discovery Anal. Bioanal. Chem. 2010, 398, 219-226
21. Derbyshire, E. R.; Mota, M. M.; Clardy, J. The next opportunity in anti-malaria drug discovery: the liver stage PLoS Pathog. 2011, 7 (9 e1002178
22. Chatterjee, A. Cell-based medicinal chemistry optimization of HTS hits for orally active antimalarials. Part 1: Challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). J. Med. Chem. 2013, DOI: 10.1021/jm400314m.
23. Younis, Y.; Street, L. J.; Waterson, D.; Witty, M. J.; Chibale, K. Cell-based medicinal chemistry optimization of HTS hits for orally active antimalarials. Part 2: Hits from SoftFocus kinase and other libraries. J. Med. Chem. 2013, DOI: 10.1021/jm400279y.
24. Cooper, C. B. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. J. Med. Chem. 2013, DOI: 10.1021/jm400381v.
25. Coxon, G. D.; Cooper, C. B.; Gillespie, S. H.; McHugh, T. D. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery J. Infect. Dis. 2012, 205 (Suppl. 2) S258-S264
26. Flannery, E. L.; Fidock, D. A.; Winzeler, E. A. Using genetic methods to define the targets of compounds with antimalarial activity. J. Med. Chem. 2013, DOI: 10.1021/jm400325j.